In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Apo B changes may drive diet-induced falls in inflammation, insulin resistance

Atherosclerosis 2010; Advance online publication

Women who achieve a reduction in apolipoprotein (apo) B through dieting also achieve reductions in inflammation and insulin resistance, shows research.


May Faraj (Clinical Research Institute of Montreal, Quebec, Canada) and colleagues found that the number of apo B particles, rather than their lipid content, predicted changes in high-sensitivity C-reactive protein (hsCRP) and insulin resistance.

Change in apo B levels was the factor most strongly associated with inflammatory changes, explaining 22%, 35%, and 43% of the variability in changes in the inflammatory markers hsCRP, orosomucoid, and haptoglobin, respectively. It also explained 17% of the variability in insulin sensitivity changes, as measured by hyperinsulinemic euglycemic clamping.

All these changes were independent of changes in weight or body mass index.
Indeed, changes in women’s inflammatory markers and insulin resistance appeared dependent on their baseline apo B levels, the team reports in the journal Atherosclerosis.
Women with baseline apo B levels above the median (0.97 g/l) had a significant 17% reduction in apo B while on the diet, along with a 24% reduction in hsCRP levels and a 14% increase in insulin sensitivity.

In contrast, women with lower starting apo B levels had a less than 1% reduction in apo B, their inflammatory markers remained stable, and they had only a nonsignificant rise in insulin sensitivity.

This was despite similar, significant amounts of weight and fat loss in both groups.

"We appreciate that the correlative nature of our study does not allow causal connections to be demonstrated," say the researchers.

Nevertheless, they believe their data suggest that elevated apo B plays a role in the development of insulin resistance and, consequently, Type 2 diabetes. Elevated apo B may therefore be an important therapeutic target for preventing diabetes in obese people, they conclude.

Read the abstract

MedWire ( is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2010